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Objective: To evaluate the characteristics of patients with autoimmune disease with
hypogammaglobulinemia following rituximab (RTX) and describe their long-term
outcomes, including those who commenced immunoglobulin replacement therapy.
Methods: Patients received RTX for autoimmune disease between 2003 and 2012 with
immunoglobulin G (IgG) <7g/L were included in this retrospective series.
Hypogammaglobulinemia was classified by nadir IgG subgroups of 5 to <7g/L (mild),
3 to <5g/L (moderate) and <3g/L (severe). Characteristics of patients were compared
across subgroups and examined for factors associated with greater likelihood of long term
hypogammaglobulinemia or immunoglobulin replacement.
Results: 142 patients were included; 101 (71%) had anti-neutrophil cytoplasm antibody
(ANCA) associated vasculitis (AAV), 18 (13%) systemic lupus erythematosus (SLE) and 23
(16%) other conditions. Mean follow-up was 97.2 months from first RTX.
Hypogammaglobulinemia continued to be identified during long-term follow-up.
Median time to IgG <5g/L was 22.5 months. Greater likelihood of moderate
hypogammaglobulinemia (IgG <5g/L) and/or use of immunoglobulin replacement
therapy at 60 months was observed in patients with prior cyclophosphamide exposure
(odds ratio (OR) 3.60 [95% confidence interval (CI) 1.03 – 12.53], glucocorticoid use at 12
months [OR 7.48 (95% CI 1.28 – 43.55], lower nadir IgG within 12 months of RTX
commencement [OR 0.68 (95% CI 0.51 – 0.90)] and female sex [OR 8.57 (95% CI 2.07 –
35.43)]. Immunoglobulin replacement was commenced in 29/142 (20%) and associated
with reduction in infection rates, but not severe infection rates.
Conclusion: Hypogammaglobulinemia continues to occur in long-term follow-up post-
RTX. In patients with recurrent infections, immunoglobulin replacement reduced rates of
non-severe infections.
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Tieu et al. RTX Associated HypogammaglobulinemiaINTRODUCTION
B cell depletion plays a key role in the management of many
autoimmune diseases. Rituximab (RTX) is licensed for use in
rheumatoid arthritis (RA) and AAV, and clinical trials have
evaluated RTX in other autoimmune conditions including SLE.
Despite limited evidence of hypogammaglobulinemia in patients
receiving RTX in these studies, it has been consistently identified in
observational studies of patients with autoimmune disease (1–7).
Lower baseline immunoglobulin G (IgG) levels, including
levels within population norms, have been associated with
subsequent hypogammaglobulinemia (2, 4, 6, 7). An association
between cumulative RTX exposure and hypogammaglobulinemia
has not been demonstrated (2–4, 7).
Although there is no universal IgG threshold for
hypogammaglobulinemia, the clinical significance of
hypogammaglobulinemia lies in the resultant susceptibility to
infection. Extrapolated from the treatment of patients with common
variable immunodeficiency (CVID), prophylactic antibiotics and
immunoglobulin replacement therapy are considered where there is
a combination of hypogammaglobulinemia, poor vaccination
responses, and recurrent and/or severe infection.
Although a proportion of patients with hypogammaglobulinemia
have been identified following RTX therapy for autoimmune disease
in several studies, their longer-term outcomes, including the effects of
immunoglobulin replacement therapy, remain unclear.
In a previous study, from which this study cohort derives,
135/243 (56%) patients with systemic autoimmune disease
treated with RTX developed hypogammaglobulinemia (4). This
was classified as mild (5 to <7 g/L) in 72 (53%), moderate (3 to <5
g/L) in 53 (39%) and severe (<3 g/L) in 10 (7%). In this study, we
sought to evaluate the long-term outcomes of patients with
previously identified hypogammaglobulinemia.OBJECTIVES
1. To explore the characteristics of patients with autoimmune
disease who develop RTX associated hypogammaglobulinemia
and their long-term outcomes.
2. To examine the outcomes of patients with autoimmune disease
which develop RTX associated hypogammaglobulinemia
requiring immunoglobulin replacement therapy.METHODS
Patients with multi-system autoimmune disease who had
received RTX between February 2003 and November 2012 and
had an IgG <7 g/L on at least two occasions were included in this
single center, retrospective cohort form the Vasculitis and Lupus
Clinic, Addenbrooke’s Hospital, Cambridge, United Kingdom.
Data were collected until August 2017 or last recorded follow-up.
A previous report from this cohort described immunoglobulinFrontiers in Immunology | www.frontiersin.org 2outcomes in 243 patients who had received RTX for the
treatment of multi-system autoimmune disease up to
November 2012 (4). This report includes extended follow-up
of 142 patients who met the above inclusion criteria.
Patients received a standard departmental dose of 2x1g a
fortnight apart followed by 1g every 6 months for 2 years.
Extension of RTX course and shortened treatment regimens
occurred when clinically appropriate. At the time of treatment
for these patients, biosimilar products were not available. Clinical
assessments and laboratory data were typically obtained 6-
monthly, prior to each dose of RTX. Interval data, where
available, were also collected.
Patients were excluded if paraproteinemia was detected at any
time during follow-up. All immunoglobulin results during periods
of nephrotic range proteinuria and for 3 months following plasma
exchangewere excluded fromanalyses. Patientswere categorizedby
absolute nadir IgG levels, as mild (5 to <7 g/L), moderate (3 to <5
g/L), and severe (<3 g/L). Infection was defined as any presumed or
confirmed infection warranting the use of an oral antimicrobial
agent. Severe infection was defined as a presumed or confirmed
infection requiring an intravenously administered antimicrobial
and/or hospital admission.
Data collected on each patient included age at diagnosis, gender,
disease diagnosis and manifestations, age, date, and indication for
first RTX prescription, cumulative RTX dose, use of
immunosuppressive agent(s) pre-RTX, concurrently and post-
RTX, prednisolone use at RTX commencement, and at 6 monthly
intervals until 24months post-RTX, infections,mortality, antibiotic
prophylaxis and use and duration of immunoglobulin replacement
therapy (intravenous or subcutaneous). Prednisolone was the
standard oral glucocorticoid prescribed, with equivalent efficacy
to prednisone. Laboratory datawere collected for each patient from
1 month prior to rituximab to last follow-up, including IgG, IgM
and IgA levels, lymphocyte, andneutrophil counts, andCD19, CD4
and CD8 counts. Flow cytometry for lymphocyte subsets were not
routine prior to every RTX infusion.Where available, B cell subsets
and antibody titers to pneumococcal, haemophilus, varicella,
measles, mumps, rubella, and tetanus were collected.
Concurrent immunosuppression was defined as the use of an
immunosuppressive agent for at least 6 weeks from RTX
commencement, except for cyclophosphamide where any use within
the first 6 weeks was included. Post-RTX immunosuppression was
defined as use of an immunosuppressive agent at least 6 weeks after
RTX commencement, for at least 3 months.
In the setting of hypogammaglobulinemia, immunoglobulin
replacement therapy was typically commenced in patients with
recurrent and/or severe infections following specialist clinical
immunology evaluation. This generally included the assessment of
infection rates, and laboratory parameters including lymphocyte
subsets and vaccine responses to Streptococcus pneumoniae and
Haemophilus influenzae, and a trial of prophylactic antibiotics.
Prophylactic antibiotic choice was individualized where possible;
azithromycin was typically used if not available microbiological or
antibiotic sensitivitydatawasavailable. Intravenous immunoglobulin
replacement therapy was commenced, and patients transitioned to
self-administered subcutaneous administration where appropriate.May 2021 | Volume 12 | Article 671503
Tieu et al. RTX Associated HypogammaglobulinemiaIntravenous immunoglobulin was not used for treatment of
underlying autoimmune disease in these patients.
In accordance with the UK National Health Service Research
Ethics Committee guidelines, ethics approval was not required as
this work comprises anonymous retrospective data and all
treatment decisions were made prior to our evaluation.
Dichotomous outcomes are summarized as proportions.
Continuous outcomes are summarized as mean and standard
deviation if normally distributed, otherwise as median and
interquartile range. Comparisons of categorical variables across
the immunoglobulin categories were analyzed using Somers’ D to
assess for the trend across nadir IgG subgroups.Nominal categorical
variableswere comparedusingChi squared testsorFisher’s exact test
as appropriate. Continuous variables have been compared using
Kruskall-Wallis tests. In patients receiving immunoglobulin
replacement therapy, infection and severe infection rates were
compared by Wilcoxon sign ranked tests. Nadir IgG in the first 12
months were used to examine outcome at 60 and 100 months
following the first dose of RTX. A multivariable logistic regression
model was used to model outcome (IgG <5g/L or on
immunoglobulin replacement therapy) at 60 months. Prespecified
explanatory variables were included using a step-wise approach.
Model fit was assessed using -2log likelihood, Cox & Snell R square
andNagelkerke R square values. Statistical analyses were performed
inSPSS version24andfigureswereproducedusingGraphpadprism
version 7 and R (ggalluvial package).RESULTS
Long-term clinical and immunoglobulin data were available for 142
patientswithhypogammaglobulinemia.Mildhypogammaglobulinemia
was recorded in 40/142 (28.2%), moderate in 66/142 (46.5%) and
severe in 36/142 (25.4%) patients. Mean follow-up was 97.2 months;Frontiers in Immunology | www.frontiersin.org 3and was longer in lower nadir IgG subgroups (Table 1). Patients with
more severe hypogammaglobulinemia were younger at diagnosis and
first RTX (Table 1). AAV was the most common indication for RTX
(71%) andmost patients receivedRTX for themanagement of relapsing
(25%) or refractory (69%) disease (Table 1). There was no difference in
indication forRTX(new, relapsing,or refractorydisease),orbydiagnosis
(p=0.27,datanot shown)bysubgroup.Seventyonepercentwere female,
with a greater proportion in patients with moderate and severe
hypogammaglobulinemia (Table 1).
Immunosuppression and Development of
Hypogammaglobulinemia
Exposure to mycophenolate mofetil prior to RTX was
more common in patients with moderate or severe
hypogammaglobulinemia (Table 2). Prednisolone use at 12
and 24 months following RTX commencement were associated
with lower nadir IgG (Table 2). Cumulative RTX dose and prior
exposure to other immunosuppressive agents were not
associated with a lower nadir IgG (Table 2).
Immunoglobulin Levels Over Long-Term
Follow-Up
Baseline values were often collected after commencement of
glucocorticoids; mean IgG at baseline was 7.45 (standard
deviation (SD) 3.1), mean baseline IgM was 0.8 (SD0.5) and
mean baseline IgA was 1.6 (0.8).
Moderate (IgG <5 g/L) and severe (IgG <3 g/L)
hypogammaglobulinemia and use of immunoglobulin replacement
therapy was increasingly observed with longer follow-up (Figure 1).
Median time tomoderatehypogammaglobulinemiawas22.5months
[IQR 3.0 to 61.5] and to severe hypogammaglobulinemia was 24.5
months [IQR 4.0 to 80.8].
Of the patients who were followed up to 60 months post-RTX
(n=124), substantial change was observed in IgG levels overTABLE 1 | Patient characteristics.
All (n = 142) Mild (n = 40) Moderate (n = 66) Severe (n = 36)
Total follow-up (months) 97.2 ± 36.4 87.5 ± 33.7 95.7 ± 34.1 110.6 ± 40.1
Age (years) 45.2 ± 17.6 47.9 ± 17.7 47.6 ± 16.7 37.4 ± 17.2
Age at first RTX (years) 51.4 ± 16.5 55.8 ± 15.8 52.4 ± 15.2 44.2 ± 17.7
Disease duration (months) 43.1 [13.2 – 101.7] 63.2 [10.8 – 159.2] 31.7 [11.7 – 76.8] 56.0 [19.4 – 97.7]
Female 101/142 (71) 21/40 (53) 50/66 (76) 30/36 (83)
Diagnosis
AAV 101/142 (71) 30/40 (75) 48/66 (73) 23/36 (64)
GPA 69/101 (68) 21/30 (70) 34/48 (71) 14/23 (61)
MPA 15/101 (15) 4/30 (13) 6/48 (13) 5/23 (22)
EGPA 17/101 (17) 5/30 (17) 8/48 (17) 4/23 (17)
SLE 18/142 (13) 5/40 (13) 6/66 (9) 7/36 (19)
Other* 23/142 (16) 5/40 (13) 12/66 (18) 6/36 (17)
Disease state
New 8/140 (6) 1/39 (3) 5/66 (8) 2/35 (6)
Relapse 35/140 (25) 10/39 (26) 16/66 (24) 9/35 (26)
Refractory 97/140 (69) 28/39 (72) 45/66 (68) 24/35 (69)May 2021 | Volume 1Mild: nadir IgG 5 to < 7 g/L, Moderate: nadir IgG 3 to < 5 g/L, Severe: nadir IgG < 3 g/L.
*other: Undifferentiated connective tissue disorder (4), Neuromyelitis optica (3), Undifferentiated vasculitis (2), Behcet’s syndrome (2), polychondritis (2), mixed connective tissue disease (2),
IgA vasculitis (1), cryoglobulinemic vasculitis (1), polyartertitis nodosa (1), Cogan’s syndrome (1), Takayasu arteritis (1), myasthenia gravis (1), cryoglobulinemic vasculitis (1).
AAV, ANCA-associated vasculitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; SLE, systemic
lupus erythematosus.
Mean ± standard deviation, median [interquartile range].2 | Article 671503
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within the first 12 months of RTX administration, 17/37 (45%)
patients recovered to an IgG ≥5 g/L without the need for
immunoglobulin replacement therapy at 60 months. A further 8/37
(22%) had commenced immunoglobulin replacement therapy, and
the remaining 12/37 (32%) remained hypogammaglobulinemiawith
an IgG <5 g/L at 60 months.
In a multivariable logistic regression model, cyclophosphamide
use prior to RTX, lower nadir IgG in the first 12 months,
prednisolone use at 12 months following RTX, and female sex
were associated with an increased likelihood of moderate
hypogammaglobulinemia and/or requiring immunoglobulin
replacement 60 months after RTX commencement. This model
was additionally adjusted for age at RTX commencement,Frontiers in Immunology | www.frontiersin.org 4mycophenolate use prior to RTX and total cumulative RTX
(Table 3).
Cumulative RTX dose was not associated with a greater
likelihood of moderate/severe hypogammaglobulinemia or
requiring immunoglobulin replacement therapy 60 months
after RTX commencement. The inclusion of disease duration
prior to RTX and number of immunosuppressive agents used
post-RTX did not improve model fit or alter overall
interpretation. A model inclusive of nadir IgM values within
the first 12 months improved model fit, with no change in
interpretation (Table 3).
Hypogammaglobulinemia and Infection
Overall, infection rates were low. Severe and non-severe
infections predominantly involved the respiratory tract (65%
and 58% respectively). There were no differences in infection
rates between patients with mild, moderate, and severe
hypogammaglobulinemia (Figure 3A). A subset of patients,
however, were referred for further assessment and/or
commenced prophylactic therapy due to recurrent infections.
Peripheral blood immunophenotyping was available in 30
patients at the time of Clinical Immunology assessment; CD19+
lymphocytes were detectable in 11 (37%). Where sufficient B cells
were identified in 8 of these patients (7 with AAV and 1 with SLE),
further B cell subset analyses were performed. This revealed a
pattern of high naïve (IgM+IgD+CD27-) and low switched
memory (IgM-IgD-CD27+) B cells in all patients (Supplementary
Table 1).
Pneumococcal antibody titers were available in 28 patients
with recurrent infection, with only 9 having protective antibody
titers to at least 7 of the 13 serotypes tested. In those who went onTABLE 2 | Use of immunosuppressive agents in patients with hypogammaglobulinemia.
All (n = 142) Mild (n = 40) Moderate (n = 66) Severe (n = 36) p
Cumulative RTX (g) 9.0 ± 5.1 8.5 ± 4.7 9.8 ± 5.6 8.1 ± 4.4 0.23
Pre-RTX immunosuppression
Cyclophosphamide 107/142 (75) 29/40 (73) 49/65 (75) 28/36 (78) 0.79
Cumulative cyclophosphamide dose (g) 12.0 [6.0 – 26.0] 12.0 [5.8 – 27.8] 11.5 [6.0 – 17.3] 11.0 [5.7 – 27.0] 0.91
Azathioprine 88/141 (62) 27/40 (68) 39/65 (60) 22/36 (61) 0.54
Mycophenolate mofetil 94/141 (67) 25/40 (63) 39/65 (60) 30/36 (83) 0.05
Methotrexate 36/141 (26) 10/40 (25) 20/65 (31) 6/36 (17) 0.42
Intravenous immunoglobulin 22/141 (16) 7/40 (18) 8/65 (12) 7/36 (19) 0.86
Plasma exchange 16/141 (11) 4/40 (10) 5/65 (8) 7/36 (19) 0.27
No. immunosuppressive medications 3.0 [2.0 – 4.0] 3.0 [2.0 – 3.0] 3.0 [2.0 – 3.0] 3.0 [2.0 – 4.0] 0.49
Concurrent immunosuppression
Cyclophosphamide 25/141 (18) 6/40 (15) 13/66 (20) 6/35 (17) 0.77
Mycophenolate mofetil 21/141 (15) 5/40 (13) 9/66 (14) 7/35 (20) 0.39
Plasma exchange 10/141 (7) 4/40 (10) 3/66 (5) 3/35 (9) 0.79
Post-RTX immunosuppression
Cyclophosphamide 20/142 (14) 6/40 (15) 8/66 (12) 6/36 (17) 0.87
Mycophenolate mofetil 27/142 (19) 5/40 (13) 14/66 (21) 8/36 (22) 0.25
No. immunosuppressive medications 0.0 [0.0 – 1.0] 0.5 [0.0 – 1.0] 0.0 [0.0 – 1.0] 1.0 [0.0 – 1.8] 0.44
Prednisolone
Baseline 115/121 (95) 36/38 (95) 53/55 (96) 26/28 (93) 0.82
6 months 120/133 (90) 31/39 (79) 61/63 (97) 28/31 (90) 0.15
12 months 113/137 (82) 27/39 (69) 56/64 (88) 30/34 (88) 0.04
24 months 98/133 (74) 22/37 (59) 48/62 (77) 28/34 (82) 0.03May 2021 | Volume 12 | Article 67Mild: nadir IgG 5 to < 7 g/L, Moderate: nadir IgG 3 to < 5 g/L, Severe: nadir IgG < 3 g/L.
RTX, rituximab. Proportion (%), median [interquartile range].FIGURE 1 | Cumulative incidence of hypogammaglobulinemia and
immunoglobulin replacement therapy commencement during follow-up.1503
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patients tested (22%) had protective pneumococcal antibody
levels, and a post-vaccination response was demonstrated in
only 1/9 (11%) recorded.
Antibiotic Prophylaxis and Immunoglobulin
Replacement Therapy
Antibiotic prophylaxis was initiated in 53 (37%) of patients;
greater antibiotic prophylaxis use was observed in patients with
moderate and severe hypogammaglobulinemia (Figure 3B). Of
the patients who commenced antibiotic prophylaxis, 42 (79%)
were AAV patients, 6 (11%) had SLE and 5 (9%) other
autoimmune conditions. Immunoglobulin replacement therapy
was initiated in 27/53 (51%) patients who had commenced
antibiotic prophylaxis.
Immunoglobulin replacement therapy was commenced in 29
patients; with mild hypogammaglobulinemia in 1 (3%) patient,
moderate hypogammaglobulinemia in 9 patients (31%) and
severe hypogammaglobulinemia in 19 patients (66%). Of the
patients commencing immunoglobulin replacement therapy, 21
(72%) had a diagnosis of AAV, 4 (14%) SLE and 4 (14%) otherFrontiers in Immunology | www.frontiersin.org 5autoimmune diseases. Immunoglobulin replacement therapy
was commenced a median of 71 months after first RTX. In
patients commencing immunoglobulin replacement therapy,
infections reduced (median [IQR] 1.02 infections/year [0.54 –
1.88] to 0.13 infections/year [0.00 – 0.35], p <0.001, Figure 3C).
Annual severe infection rates were not reduced during
immunoglobulin replacement therapy in these patients. After
removal of two outliers with recurrent respiratory tract infections
requiring antibiotics, there remained no difference in severe
infection rates.
At the time of data collection or last recorded follow-up, 20 of 29
patients were continuing to receive immunoglobulin replacement
therapy, 4 had died and 5 had ceased immunoglobulin replacement
therapy. Of the four who died, the causes of death were respiratory
sepsis in a patient with AAV, decompensated liver disease and
pneumonia in a patient with IgA vasculitis, refractory vasculitis in a
patient with AAV andwas unknown in a patient with AAV. Of the
five who had ceased immunoglobulin replacement therapy, 2 were
intolerant and 3 were weaned off immunoglobulin replacement
therapy without recurrent infection; 1 subsequently recommenced
immunoglobulin replacement therapyowing to recurrent infection,FIGURE 2 | Change in IgG strata between month 12 and month 60 of follow-up.TABLE 3 | IgG < 5 g/L or immunoglobulin replacement at 60 months.
Model 1 OR (95% CI) p- value Model 2 OR (95% CI) p-value
Age at RTX commencement 0.98 (0.95 – 1.01) 0.21 0.97 (0.94 – 1.01) 0.10
Female 7.56 (1.88 – 30.48) 0.004 8.57 (2.07 – 35.43) 0.008
Pre-RTX cyclophosphamide 3.31 (1.00 – 10.96) 0.05 3.60 (1.03 – 12.53) 0.04
Pre-RTX mycophenolate 2.16 (0.75 – 6.26) 0.16 2.04 (0.70 – 5.95) 0.20
Nadir IgG (0 – 12 m) 0.67 (0.50 – 0.90) 0.008 0.68 (0.51 – 0.90) 0.008
Prednisolone use at 12 m 6.19 (1.12 – 33.31) 0.03 7.48 (1.28 – 43.55) 0.03
Total cumulative RTX 0.91 (0.81 – 1.02) 0.09 0.91 (0.81 – 1.02) 0.11
Nadir IgM (0 – 12 m) – 0.12 (0.01 – 1.05) 0.06May 2021 | Volume 12 | ArticleRTX, rituximab; Ig immunoglobulin; m, month, OR, odds ratio, CI, confidence interval.671503
Tieu et al. RTX Associated Hypogammaglobulinemia1 has had IgG recovery to normal levels (>7 g/L), and 3 have
remained off immunoglobulin replacement therapywith stable IgG
levels <5 g/L.DISCUSSION
We report on 142 patients with multi-system autoimmune disease
with RTX associated hypogammaglobulinemia, their long-termFrontiers in Immunology | www.frontiersin.org 6outcomes and response to immunoglobulin replacement therapy.
Overall, 102/142 (72%) had moderate hypogammaglobulinemia
and 36/142 patients (25%) severe hypogammaglobulinemia.
Factors associated with lower nadir IgG levels were prior
mycophenolate use and prednisolone use 12 and 24 months after
RTX initiation. Prior cyclophosphamide, prednisolone at 12
months after RTX initiation, nadir IgG in the first 12 months of
RTX commencement and female sex were associated with an
increased likelihood of moderate/severe hypogammaglobulinemiaA
B
C
FIGURE 3 | (A) Annual infection and severe infection rate by IgG subgroup. (B) Commencement of antibiotic (Abx) prophylaxis and IgG replacement by IgG group.
(C) Infection and severe infection rates in patients without IgG replacement and during IgG replacement.May 2021 | Volume 12 | Article 671503
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RTX commencement. Antibiotic prophylaxis was used in 53/142
(37%) patients and immunoglobulin replacement therapy
commenced in 29/142 (20%) in whom infection rates but not
severe infection rates were reduced.
The majority of patients included in this study had refractory
SLE and AAV. There is substantial consistent evidence that RTX
is beneficial in patients with AAV in both induction and
maintenance of remission (8–10). Although data for RTX in
SLE has been mixed, observational studies have demonstrated
benefit (11, 12). Although hypogammaglobulinemia has been
identified in multiple observational studies, the occurrence of
hypogammaglobulinemia in this cohort is higher than previous
estimates (7, 13–16). This cohort had a longer duration of follow-
up, with nadir IgG levels occurring many months or years after
commencing RTX therapy. Mean follow-up was 8 years,
compared with up to an average follow-up of 4 years in other
studies (2, 7, 13–18).
The rate of hypogammaglobulinemia may also be influenced
by diagnosis. Although most patients in this study had AAV,
other studies of hypogammaglobulinemia have included greater
proportions of patients with RA (not included in this study) and
SLE (13% of this cohort) (1, 16, 18). Thiel and colleagues have
demonstrated delayed B cell recovery following RTX in patients
with AAV compared with RA and SLE, suggesting a distinct
underlying or acquired B cell dysfunction in these patients (19).
Notably, cumulative RTX doses are higher in this study than
other reports (6, 7, 15, 17). This is likely influenced by multiple
factors including the duration of follow-up and high proportion
of patients with longstanding relapsing or refractory disease in
this cohort. An association between cumulative RTX and
hypogammaglobulinemia has previously been postulated (6),
but not identified in other studies (2, 4, 7). In this study, there
was no difference in cumulative RTX dose across the subgroups
and was not associated with greater likelihood of moderate/
severe hypogammaglobulinemia or requiring immunoglobulin
replacement therapy at 60 months in an adjusted logistic
regression model.
The impact of other immunosuppressive agents used prior to,
in conjunction with or after RTX in the development of
hypogammaglobulinemia has been difficult to delineate. Of
note, mean baseline immunoglobulin levels were low-normal
at baseline. In this study, mycophenolate and cyclophosphamide
were the most common non-glucocorticoid immunosuppressive
agents used. In the multivariable logistic regression model
accounting for age, sex and prednisolone use post-RTX, prior
cyclophosphamide, but not mycophenolate use increased the
likelihood of moderate or severe hypogammaglobulinemia 60
months after RTX initiation. Venhoff and colleagues observed
prolonged B cell depletion in patients who received RTX after
previous cyclophosphamide use compared with RTX alone (20).
In this study, 54% of patients who had received prior
cyclophosphamide developed hypogammaglobulinemia,
compared with 21% who received RTX alone.
Glucocorticoids alone have also been implicated in the
development of hypogammaglobulinemia, and the impact ofFrontiers in Immunology | www.frontiersin.org 7prolonged or greater glucocorticoid use in conjunction with
RTX or other immunosuppressive agents on immunoglobulin
levels requires further study (21). In this cohort, prednisolone
use at 12 and 24 months were associated with lower nadir
immunoglobulin levels. In the multivariable model examining
outcomes at 5 years, prednisolone use at 12 months was
associated with increased likelihood of moderate or severe
hypogammaglobulinemia and/or immunoglobulin replacement.
The use of prednisolone at 12 months was observed in 82.5% of
patients, reflective of clinical practice in patients with historically
more difficult to control, longstanding disease. Ongoing efforts to
minimize glucocorticoid exposure remain important to the
chronic management of these patients.
Of interest, there were more female patients were
more likely to have more likely to have moderate/severe
hypogammaglobu l inemia and/or have commenced
immunoglobulin replacement therapy at 60 months. Cross
sectional studies suggest that immunoglobulin levels decline with
age, with limited differences betweenmales and females in adult age
ranges (22–24). In post-hoc analyses of a trial evaluating induction
therapy in AAV, female patients receiving RTX had higher serum
RTX levels compared with males despite using body surface
area dosing (25). Importantly, however, although higher serum
levels of RTX were associated with a longer time to B cell
repopulation, this was not associated with fewer relapses up to 18
months of follow-up. This association requires further assessment
in larger cohorts and could have implications for dosing based on
sex if confirmed.
Infections remain the key concern in patients with
hypogammaglobulinemia. In a mixed cohort of patients
receiving RTX for cancer (77.7%) and rheumatologic
conditions (27.7%), severe infection rates were greater in
patients with hypogammaglobulinemia (26). This was observed
in early follow-up 12 months after RTX by MD Yusof and
colleagues who in a mixed cohort of patients with autoimmune
rheumatic diseases, identified an increased likelihood of severe
infections in patients with hypogammaglobulinemia (16).
The use of immunoglobulin replacement therapy in patients with
hypogammaglobulinemia associated with immunosuppression is
extrapolated from experience in the management of the
heterogenous group of patients with CVID. Both groups share a
predisposition to infection, hypogammaglobulinemia, and impaired
vaccination responses. In CVID, a reduction in respiratory tract
infections has been demonstrated in small cohorts after
commencement of immunoglobulin replacement therapy (27–29).
The efficacy of immunoglobulin replacement therapy in patients
with hypogammaglobulinemia and hematological malignancies
has also been demonstrated in small cohorts (30). We observed a
reduction in infection rates after initiation of immunoglobulin
replacement therapy, supporting the efficacy of immunoglobulin
replacement therapy in this population of patients with systemic
autoimmune disease.
Importantly, despite the reduction in infections requiring
antimicrobial therapy, the same benefit was not observed for
severe infections. The majority of severe infections in these
patients were respiratory tract infections; in this patientMay 2021 | Volume 12 | Article 671503
Tieu et al. RTX Associated Hypogammaglobulinemiapopulation, disease related airways damage and colonization of
the respiratory tract commonly contribute to chronic and
recurrent infections, which may not be mitigated by
immunoglobulin replacement. Age and other comorbidities
may additionally influence infections in this cohort of patients
with refractory and relapsing disease.
Given the patient and health care burdens of ongoing
immunoglobulin replacement therapy, and increasing concerns
regarding supply of this limited resource, trials of immunoglobulin
replacement therapy cessation are considered. However, the most
appropriate approach to this remains unknown. Recovery of
immunoglobulin levels was observed in several individuals in
longer term follow-up. In this single center study, of the 29
patients who commenced immunoglobulin replacement therapy,
it was successfully ceased in 4 of the 5 patients in whom this was
attempted. Although a very limited experience is presented in
this study, it highlights the possibility of cessation of
immunoglobulin replacement.
Again, albeit in small numbers, the pattern of high naïve and
low switched memory B cells observed in a subset of these patients
with hypogammaglobulinemia despite B cell repopulation
warrants further investigation. Although a possible treatment
effect, this could be representative of an associated underlying B
cell dysfunction, which has been suggested in the associations
between CVID and autoimmunity (31, 32).
Limitations of this study include the retrospective design,
introducing selection bias in choice of treatments and total doses.
Long-term follow-up in patients who have difficult to control
rare autoimmune disease has inherent challenges. Though
missing data, particularly for infection and severe infections,
which were often not culture proven, is an important limitation,
this group of patients typically have close clinical review focusing
on infections, an important contributor to morbidity in this
group of patients. The lack of control group for comparisons of
infection and severe infection rates is a limitation to this
study. Some studies have drawn comparisons between
cyclophosphamide and rituximab treated patients. As
refractory disease or disease relapse are common in long term
follow-up, overlap of medications are common, and limit
comparisons between groups.
In this study evaluating long-term outcomes of patients with
RTX associated hypogammaglobulinemia, we have observed
clinically significant hypogammaglobulinemia in a high
proportion of patients, and an increasing incidence ofFrontiers in Immunology | www.frontiersin.org 8hypogammaglobulinemia over time. The rates observed
highlight the need for ongoing immunoglobulin monitoring in
patients who have previously or continue to receive RTX. The
use of prior immunosuppressive therapies, prolonged
glucocorticoid use and female gender were associated with
hypogammaglobulinemia long-term. Additionally, a reduction
in infection in those receiving immunoglobulin replacement
therapy for recurrent infection, provides evidence of its efficacy
in this population of immunodeficient individuals. The risks and
consequences of hypogammaglobulinemia should be considered
with RTX therapy in multi-system autoimmune disease.DATA AVAILABILITY STATEMENT
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